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The ubiquitin-editing enzyme A20 suppresses nuclear factor-jB (NF-jB) activation and tumor
necrosis factor-a (TNF-a)-induced apoptosis in a deubiquitinating and ubiquitin ligase activity-de-
pendent manner. Although recent studies revealed that A20 regulates NF-jB independently of its
enzymatic activity through its seventh zinc ﬁnger motif (ZnF7), the involvement of ZnF7 in TNF-
a-induced apoptosis is not clear. In this study, ZnF7 was found to be important for A20-mediated
suppression of TNF-a-induced apoptosis. We also found that the ubiquitin ligases cIAP1/2 are
required for A20 to suppress TNF-a-induced apoptosis. Because A20 binds to cIAP1/2 through
ZnF7, these results suggest that A20 may control cIAP1/2 when suppressing TNF-a-induced
apoptosis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
TNF-a is a multifunctional cytokine that regulates various cellu-
lar events including proliferation, differentiation, and death [1,2].
TNF receptor I (TNF-RI) is the most prevalent receptor for TNF-a.
TNF-RI is a member of the death receptor superfamily that acti-
vates the transcription factor NF-jB and induces apoptosis [3].
Binding of TNF-a to TNF-RI induces its oligomerization and pro-
motes the formation of a plasma membrane-associated complex
[4]. This initial complex is referred to as complex-I and is com-
posed of TRADD, RIP1, TRAF2, cIAP1 and 2 (cIAP1/2), and the linear
ubiquitin chain assembly complex (LUBAC) [5]. cIAP1/2 bind to
TRAF2 and function as the ubiquitin E3 ligase complex (cIAP1/2:TRAF2) that promotes the synthesis of Lys48- or Lys63-linked
polyubiquitin chains [6,7]. LUBAC is composed of HOIL-1, HOIP,
and Sharpin and catalyzes the formation of Met1-linked polyubiq-
uitin chains [8–10]. Although RIP1 has serine/threonine kinase
activity, it acts as an adaptor protein within complex-I. RIP1 is
polyubiquitinated by cIAP1/2:TRAF2 and LUBAC. Polyubiquitin
chains of RIP1 serve as scaffolds for downstream signaling mole-
cules such as TAK1 and IKK [11,12]. TAK1 is auto-activated on
the ubiquitin chains and induces the phosphorylation and activa-
tion of IKK. IKK facilitates the phosphorylation and subsequent
degradation of IjBa, thereby allowing NF-jB activation [13].
Binding of TNF-a to TNF-RI also induces the formation of a sec-
ond protein complex in the cytosol [4]. This complex is referred to
as complex-II and is composed of RIP1, RIP3, FADD, and caspase-8.
Deubiquitination of RIP1 by deubiquitinating enzymes is required
for the formation of complex-II. Upon the formation of complex-
II, caspase-8 is activated by auto-cleavage and then induces apop-
tosis [5]. Because TNF-a-mediated NF-jB activation induces the
expression of anti-apoptotic genes and suppresses complex-II-me-
diated apoptosis, TNF-a-induced apoptosis occurs only in the
absence of de novo protein synthesis or in cells lacking crucial
NF-jB activators [14,15].
The ubiquitin-editing enzyme A20 is composed of an ovarian
tumor (OTU) domain and seven zinc ﬁnger motifs (ZnFs). A20 func-
tions as a deubiquitinating enzyme through the OTU domain and
as a ubiquitin E3 ligase through the fourth ZnF (ZnF4) [16]. The
most important biological role of A20 is terminating NF-jB
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mune diseases and B-cell lymphoma [17–19]. To terminate NF-
jB activation, A20 promotes the degradation of Lys63-linked
polyubiquitin chains on RIP1 and its subsequent proteasomal
degradation by adding Lys48-linked polyubiquitin chains [16]. In
addition, A20 disrupts the NF-jB-activating ubiquitin ligase com-
plexes through its deubiquitinating activity [20].
A20 is involved in preventing death receptor-induced apoptosis
[17]. Previous studies reported that A20 blocks death receptor-in-
duced apoptosis in a manner dependent on its ubiquitin-editing
activity. The deubiquitinating activity of A20 reverses the polyu-
biquitination of caspase-8, which is required for its activation upon
stimulation by the death receptor ligand TRAIL [21]. The ubiquitin
ligase activity of A20 induces Lys63-linked polyubiquitination of
RIP1 upon TRAIL stimulation, and the synthesized polyubiquitin
chains bind to caspase-8 and suppress its dimerization and activa-
tion [22].
In contrast to these observations, emerging evidence revealed
that A20 also functions in an enzymatic activity-independent man-
ner in NF-jB suppression. A20 binds directly to Lys63- and Met1-
linked polyubiquitin chains through its seventh ZnF (ZnF7) and
suppresses IKK activation [23–25]. Recently, we also found that
A20 binds directly to cIAP1/2 through ZnF7 and regulates their
roles independently of its enzymatic activity [26]. Although these
observations showed that ZnF7 is involved in regulating NF-jB
activation, its role in death receptor-mediated apoptosis is not
clear. Therefore, the current study was designed to determine the
role of ZnF7 in A20-mediated suppression of TNF-a-induced
apoptosis.
2. Materials and methods
2.1. Plasmids and antibodies
The plasmids used in this study were described previously [26].
In brief, human and mouse A20 cDNAs were generated by PCR and
inserted into pMXs retroviral vectors that were obtained from T.
Kitamura (University of Tokyo, Japan). An myc tag was added at
the N-terminus of the cDNAs. The antibodies used in this study
are shown in Supplementary Table S1.
2.2. Cells and transfection, western blot analyses, and
immunoprecipitation
Cell culture conditions were described previously [26]. A20-de-
ﬁcient mouse embryonic ﬁbroblasts (MEFs) were kindly provided
by A. Ma (University of California at San Francisco, USA) [17].
Stable cell pools were established as described previously [26].
Recombinant human TNF-a and IL-1a were purchased from
Peprotech (Rocky Hill, NJ). MV-1 was kindly provided by Y.
Demizu (National Institute of Health Sciences, Japan).
Necrostatin-1 was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). z-VAD-fmk was purchased from Peptide
Institute (Osaka, Japan). Western blot analyses and immunoprecip-
itation were performed as described previously [26].
2.3. GST pull-down assay
Human cDNA encoding the TNF-a C-terminus extracellular
domain (Val77-Leu233) was generated by PCR with the sense pri-
mer 50-AAAGAATTCGTCAGATCATCTTCTCGAACC-30 and the anti-
sense primer 50-TTTGCGGCCGCTCACAGGGCAATGATCCCAAAG-30.
The cDNA generated was digested with EcoRI and NotI, and cloned
into the pGEX-6P-1 vector that was pre-digested with the same
enzymes. GST-TNF-a was expressed in Escherichia coli DH5a andpuriﬁed using Glutathione Sepharose 4B (GE Healthcare,
Waukesha, WI). Puriﬁed GST-TNF-a was dialyzed with phos-
phate-buffered saline (PBS). Contaminating endotoxins were
removed with Detoxi-Gel Endotoxin Removing Columns as per
the manufacturer’s instructions (Pierce, Rockford, IL). Cells were
stimulated with GST-TNF-a, washed with PBS, and then lysed in
TNE buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton
X-100, 2 mM EDTA, 2 mM Na3VO4, 10 mM NaF, 1 mM phenyl-
methylsulfonyl ﬂuoride]. The cell lysate was centrifuged to remove
cellular debris. The resulting supernatant was mixed with 15 ll of
Glutathione Sepharose 4B. After overnight incubation, the beads
were washed 3 times with TNE buffer and then suspended in
SDS-sample buffer.
2.4. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) assay
Cells were plated at 1000 cells/well in a 96-well plate and incu-
bated overnight at 37 C. The cells were then incubated with the
reagents indicated in the text for 16 h in triplicate cultures. After
this incubation period, each well was washed with PBS and incu-
bated for an additional 4 h in a 1 mg/ml MTT solution (Dojindo,
Kumamoto, Japan). The resulting crystals were dissolved in
100 ll of DMSO and the absorbance was measured at 595 nm using
an iMark microplate reader (Bio-Rad, Richmond, CA).
3. Results
3.1. ZnF7 is required for A20 to suppress NF-jB upon stimulation with
TNF-a and IL-1
Recent studies have revealed that ZnF7 is required for A20 to
suppress NF-jB activation by TNF-a [23–25]. We ﬁrst conﬁrmed
the importance of ZnF7 in TNF-a-induced NF-jB activation using
A20-deﬁcient MEFs reconstituted with wild-type A20 or its ZnF7
mutant (ZnF7mt). ZnF7mt has alanine substitutions in the con-
served cysteine residues of ZnF7 (mouse A20, C764A/C767A;
human A20, C779A/C782A) [23]. NF-jB activation was evaluated
by determining the phosphorylation of IKK and IjBa. TNF-a-in-
duced NF-jB activation was signiﬁcantly reduced in cells reconsti-
tuted with wild-type A20, but not with ZnF7mt (Fig. 1A). HEK293T
cells stably expressing wild-type A20 or ZnF7mt were stimulated
with TNF-a. NF-jB activation in these cells was assessed by ana-
lyzing the phosphorylation of IjBa. Consistent with previous stud-
ies [23], NF-jB activation by TNF-awas signiﬁcantly suppressed in
HEK293T cells stably expressing wild-type A20, but not ZnF7mt
(Fig. 1B). We also analyzed the involvement of ZnF7 in NF-jB
activation by IL-1a. Similar to stimulation with TNF-a, NF-jB acti-
vation induced by IL-1a was signiﬁcantly suppressed in MEFs
reconstituted with wild-type A20, but not with ZnF7mt (Fig. 1C).
These results conﬁrmed that ZnF7 is required for A20 to suppress
NF-jB activation upon stimulation with IL-1a as well as TNF-a.
3.2. ZnF7 is required for A20 to suppress TNF-a-induced apoptosis
We next investigated the involvement of ZnF7 in the A20-medi-
ated suppression of TNF-a-induced apoptosis. To compare the sig-
niﬁcance of the enzymatic activities of A20 and ZnF7 in terms of
apoptosis, we analyzed the viability of A20-deﬁcient MEFs recon-
stituted with wild-type A20, its OTU domain mutant (OTUmt), its
ZnF4 mutant (ZnF4mt), or the ZnF7mt. The OTUmt lacks deubiqui-
tinating activity due to a mutation in the catalytic cysteine residue
(mouse A20, C103A). ZnF4mt lacks ubiquitin E3 ligase activity due
to mutations in the conserved cysteine residues (mouse A20,
C609A/C612A) [16]. Apoptosis was induced by treatment with
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Fig. 1. ZnF7 is important for A20 to suppress the activation of NF-jB in response to TNF-a and IL-1 signaling. (A) A20-deﬁcient MEFs and (B) HEK293T cells stably expressing
control vector, wild-type A20, or A20 ZnF7mt were stimulated with TNF-a (10 ng/ml) for the indicated times. Cell lysates were prepared and subjected to western blot
analyses with the indicated antibodies. (C) A20-deﬁcient MEFs stably expressing control vector, mouse wild-type A20, or A20 ZnF7mt were stimulated with IL-1a (10 ng/ml)
for the indicated times. Cell lysates were prepared and subjected to western blot analyses with the indicated antibodies.
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heximide (CHX). Cell viability was detected by the MTT assay.
The viability of A20-deﬁcient MEFs reconstituted with OTUmt or
wild-type A20 was signiﬁcantly greater than that of the control
A20-deﬁcient MEFs. This suggests that the deubiquitinating activ-
ity of A20 is not crucial for suppressing TNF-a-induced apoptosis
(Fig. 2A). Although reconstitution with ZnF4mt partially retained
the viability of A20-deﬁcient MEFs treated with TNF-a plus CHX,
reconstitution with ZnF7mt failed to improve cell viability
(Fig. 2A). Because both ZnF4mt and ZnF7mt lack ubiquitin E3 ligase
activity [23], these results suggest that, although the ubiquitin E3ligase activity of A20 is partially involved in suppressing TNF-a-
induced apoptosis, ZnF7 plays an essential role in the suppression
of apoptosis by A20 independently of its enzymatic activity.
The activation of apoptosis signaling was also analyzed by
determining levels of cleaved caspase-3 and its downstream target,
PARP. The cleavage of caspase-3 and PARP was signiﬁcantly sup-
pressed by reconstituting A20-deﬁcient MEFs with wild-type
A20, OTUmt, and, to a lesser extent, ZnF4 (Fig. 2B). However,
reconstitution with ZnF7mt did not suppress apoptosis signaling
in A20-deﬁcient MEFs (Fig. 2B). In HEK293T cells, even though cell
viabilities were not improved (Fig. 2C), TNF-a-induced cleavage of
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Fig. 2. ZnF7 is important for the suppression of TNF-a-induced apoptosis by A20. (A) A20-deﬁcient MEFs stably expressing control vector, mouse wild-type A20, or A20
mutants were treated with TNF-a (10 ng/ml) plus CHX (10 lg/ml) together with or without Necrostatin-1 (Nec-1) (20 lM) for 16 h. After treatment, cell viability was
determined using the MTT assay. Results are shown as ratios to the viability of control cells treated with CHX (10 lg/ml) alone. Data are expressed as means ± S.D. (n = 3).
Asterisks indicate the signiﬁcant differences (⁄⁄⁄p < 0.001, ⁄⁄p < 0.01) calculated by Student’s t-test. (B) A20-deﬁcient MEFs stably expressing control vector, wild-type A20, or
A20 mutants were treated with TNF-a (10 ng/ml) plus CHX (10 lg/ml) for the indicated times. Cell lysates were prepared and subjected to western blot analyses with the
indicated antibodies. (C) HEK293T cells stably expressing control vector, human wild-type A20, or A20 ZnF7mt were treated with TNF-a (10 ng/ml) plus CHX (10 lg/ml) for
16 h. After treatment, cell viability was determined as in (A). (D) HEK293T cells stably expressing control vector, wild-type A20, or ZnF7mt were treated with TNF-a (10 ng/
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or A20 mutants were treated with TNF-a (10 ng/ml), CHX (10 lg/ml), and z-VAD-fmk (100 lM) together with or without Nec-1 (20 lM) for 16 h. After treatment, cell viability
was determined as in (A).
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type A20, but not ZnF7mt, especially 120 min after stimulation
(Fig. 2D).
Caspase inhibition promotes programmed necrosis (necropto-
sis) instead of apoptosis upon TNF-a stimulation [27], and TNF-
a-induced necroptosis depends on RIP1’s kinase activity [28].
TNF-a plus CHX-induced reduction in cell viability was not blocked
by the RIP1 kinase inhibitor Necrostatin-1 (Fig. 2A), suggesting that
treatment with TNF-a plus CHX primarily causes apoptosis of
A20-deﬁcient MEFs. To investigate the involvement of A20 inTNF-a-induced necroptosis, we analyzed the viability of A20-
deﬁcient MEFs after treatment with TNF-a, CHX, and the caspase
inhibitor z-VAD-fmk. Although reconstitution with wild-type A20
or OTUmt improved the viability of A20-deﬁcient MEFs, reconstitu-
tion with ZnF4mt or ZnF7mt did not affect cell viability (Fig. 2E).
Reduction in cell viability by treatment with TNF-a, CHX, and
z-VAD-fmk was completely blocked by Necrostatin-1 (Fig. 2E).
Taken together, these results suggest that A20 suppresses TNF-a-
induced necroptosis in a manner that depends on its ubiquitin E3
ligase activity.
N. Yamaguchi, N. Yamaguchi / FEBS Letters 589 (2015) 1369–1375 13733.3. cIAP1/2 are required for the suppression of TNF-a-induced
apoptosis by A20
Because cIAP1/2 are involved in apoptosis signaling [6,29,30],
the involvement of cIAP1/2 in the A20-mediated suppression of
TNF-a-induced apoptosis was analyzed. TNF-a can induce apopto-
sis in the absence of cIAP1/2. Thus, cells were treated with the
cIAP1/2 antagonist MV-1, which promotes autoubiquitination
and degradation of cIAP1/2 [31], prior to TNF-a stimulation.
Although treatment with MV-1 alone did not affect the viability
of A20-deﬁcient MEFs, co-treatment with MV-1 and TNF-a signif-
icantly reduced their survival. Importantly, reconstitution of A20-
deﬁcient MEFs with wild-type A20 failed to block the apoptosis
induced by TNF-a plus MV-1 (Fig. 3A, B). These results suggest that
cIAP1/2 are required for A20 to suppress TNF-a-induced apoptosis.
3.4. ZnF7 is required for A20 to suppress the formation of complex-II
We hypothesized that A20 regulates cIAP1/2:TRAF2 in response
to TNF-a signaling because A20 binds to cIAP1/2. cIAP1/2 promote
polyubiquitination of RIP1 within complex-I, and depletion of
cIAP1/2 causes a reduction in RIP1 polyubiquitination [29]. The
formation of complex-I was determined by pull-down assays in
GST-TNF-a-stimulated HEK293T cells. Polyubiquitination of RIP1
and recruitment of cIAP1 and TRAF2 to complex-I were detected
in control cells (Fig. 4A). Recruitment of cIAP2 to complex-I was
not detectable, most likely because of its low expression [26]. In
contrast, polyubiquitination of RIP1 was signiﬁcantly reduced.
Moreover, recruitment of cIAP1 and TRAF2 to complex-I wasCleaved PARP
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indicated times. After incubation, cell lysates were prepared and subjected to
western blot analysis with the indicated antibodies.almost completely suppressed in A20-overexpressing cells
(Fig. 4A). As shown in previous studies [29,32], depletion of
cIAP1/2 by MV-1 reduced the polyubiquitination of RIP1 similar
to the overexpression of A20 (Fig. 4B). This suggests that the reduc-
tion in the polyubiquitination of RIP1 was caused by A20-mediated
abrogation of the recruitment of cIAP1/2:TRAF2 to complex-I in
A20-overexpressing cells. Despite the absence of cIAP1/2:TRAF2
in complex-I, the LUBAC component HOIL-1 and A20 were
recruited to complex-I (Fig. 4A), which suggests that A20 binds
to LUBAC-dependent polyubiquitin chains in complex-I.
Consistent with this hypothesis, HOIL-1 and A20 still bound to
complex-I even in cells where cIAP1/2 were depleted by MV-1
treatment (Fig. 4B and C). This cIAP1/2-independent recruitment
of LUBAC to complex-I may be involved in the residual polyubiqui-
tination of RIP1 and NF-jB activation upon TNF-a stimulation in
MV-1-treated cells (Fig. 4B and D).
We next analyzed the effect of A20 on the formation of complex-
II by immunoprecipitation of caspase-8 in lysates from HEK293T
cells treatedwith TNF-a and CHX. The association of caspase-8with
un-ubiquitinated RIP1 and FADD and the cleavage of caspase-8
were increased in response to this combined treatment. In contrast,
both changes were signiﬁcantly repressed by the expression of
wild-type A20, but not ZnF7mt (Fig. 4E). This suggests that A20 sup-
presses the formation of complex-II in a ZnF7-dependent manner.
Because cIAP1/2 are required for the suppression of apoptosis by
A20 (Fig. 3A and B), these results suggest that A20 suppresses
TNF-a-induced apoptosis by controlling cIAP1/2.
4. Discussion
cIAP1/2 are crucial ubiquitin E3 ligases that regulate NF-jB acti-
vation and apoptosis signaling. Under non-stimulated conditions,
cIAP1/2 promote Lys48-linked polyubiquitination of NF-jB-induc-
ing kinase (NIK), a key protein kinase involved in the activation of
non-canonical NF-jB, and thereby induce its proteasomal degrada-
tion [33,34]. The lymphotoxin-b receptor, a member of the TNF
receptor superfamily, promotes NIK activation [35]. Upon stimula-
tion with lymphotoxin-b, A20 is expressed and binds directly to
cIAP1/2 through ZnF7 [26]. The binding of A20 to cIAP1/2 promotes
the dissociation of TRAF2 from TRAF3, breaking the molecular
bridge that joins cIAP1/2 and NIK and thereby inhibiting polyubiq-
uitination and the subsequent degradation of NIK (Supplementary
Fig. S1A).
In the current study,we found that ZnF7and cIAP1/2 are required
for A20 to suppress TNF-a-induced apoptosis. Because our recent
study showed that A20 binds directly to cIAP1/2 through ZnF7 and
regulates their targets [26], these results suggest that A20 sup-
presses TNF-a-induced apoptosis by controlling cIAP1/2. Our pre-
sent data show that overexpressing A20 prevents the recruitment
of cIAP1/2:TRAF2 to complex-I and polyubiquitination of RIP1.
Because cIAP1/2:TRAF2 associate with RIP1 through TRAF2 [7],
these data suggest that the binding of A20 to cIAP1/2 suppresses
the association between TRAF2 and RIP1 and the subsequent
cIAP1/2-mediated polyubiquitination of RIP1. Because the presence
of un-ubiquitinatedRIP1 in complex-II promotes apoptosis, the sup-
pression of RIP1 polyubiquitination by A20 is not involved in
repressing TNF-a-induced apoptosis. Given that the expression of
A20 is induced by TNF-a [36], we hypothesize that the binding of
A20 to cIAP1/2 causes a shift in the target of cIAP1/2 from RIP1 to
another protein involved in suppressing apoptosis. This target shift
may inhibit both NF-jB activation and apoptosis signaling in the
late phase of TNF-a signaling (Supplementary Fig. S1B). This
unknown target should be determined in further studies.
A20 is frequently mutated or deleted, especially in the region
encoding ZnF7, in B-cell lymphomas [18,19]. Because ZnF7 is
important for suppressing NF-jB, and the constitutive NF-jB
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Fig. 4. ZnF7 is required for A20-mediated suppression of the formation of complex-II. (A) HEK293T cells stably expressing control vector or wild-type A20 were treated with
GST-TNF-a (50 ng/ml) for the indicated times. After incubation, GST pull-down assays were performed as described in Section 2. Input and pull-down samples were subjected
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DMSO (0.1%) for 24 h and then treated with GST-TNF-a (50 ng/ml) for the indicated times. After incubation, GST pull-down assays and subsequent western blot analyses were
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1374 N. Yamaguchi, N. Yamaguchi / FEBS Letters 589 (2015) 1369–1375activation is involved in tumorigenesis [37], it is reasonable to con-
clude that de-regulated NF-jB activation results frommutations or
deletions of A20 and is a major cause of B-cell lymphomas.
However, our present data also suggest that B-lymphocytes with
mutations or deletions in A20 are prone to undergo apoptosis upon
stimulation with TNF-a. Emerging evidence revealed that
apoptotic cells secrete mitogenic factors to induce compensatory
proliferation of neighboring cells [38,39]. Although this compen-
satory proliferation was observed primarily in epithelial cells,
recent studies showed that lymphocytes also have an ability to
promote compensatory proliferation [40]. Because chronic mito-
genic stimuli often cause tumorigenesis [38], we speculate thatthe susceptibility of B-lymphocytes with mutations or deletions
in A20 to TNF-a-induced apoptosis may be involved in the devel-
opment of B-cell lymphomas through the induction of persistent
compensatory proliferation.
In conclusion, we found that ZnF7 is important for the suppres-
sion of TNF-a-induced apoptosis by A20. Because overexpression
of A20 promotes the survival of glioma stem cells and tumor pro-
gression [41], up-regulation as well as down-regulation of the
activity of A20’s ZnF7 may be involved in tumorigenesis by induc-
ing resistance to apoptosis. Therefore, our present results suggest
that inhibiting ZnF7 may be a novel therapeutic strategy for A20-
overexpressing cancers.
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